PDS Biotechnology’s (PDSB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report released on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for PDS Biotechnology’s Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.25) EPS.

Several other brokerages also recently commented on PDSB. Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Trading Down 3.2%

Shares of NASDAQ:PDSB opened at $0.21 on Wednesday. The stock has a 50 day moving average of $0.62 and a 200 day moving average of $0.81. The company has a market cap of $11.80 million, a PE ratio of -0.33 and a beta of 1.62. PDS Biotechnology has a 12-month low of $0.20 and a 12-month high of $1.55. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). As a group, equities research analysts expect that PDS Biotechnology will post -0.45 EPS for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC purchased a new position in shares of PDS Biotechnology in the fourth quarter worth $2,182,000. BlackRock Inc. bought a new stake in PDS Biotechnology in the 2nd quarter valued at $535,000. Geode Capital Management LLC lifted its stake in PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after purchasing an additional 38,399 shares in the last quarter. Squarepoint Ops LLC lifted its stake in PDS Biotechnology by 116.1% in the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after purchasing an additional 156,662 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares during the last quarter. 26.84% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.